Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
IPO Year: 2004
Exchange: NASDAQ
Website: cytokinetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2025 | $55.00 | Overweight | Barclays |
| 2/7/2025 | $86.00 | Buy | Citigroup |
| 1/22/2025 | $80.00 | Buy | Stifel |
| 11/8/2024 | $80.00 | Outperform | RBC Capital Mkts |
| 8/13/2024 | $85.00 → $60.00 | Buy → Neutral | Goldman |
| 1/24/2024 | $61.00 → $92.00 | Buy → Neutral | UBS |
| 1/5/2024 | $60.00 → $90.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/9/2023 | $50.00 | Buy | Goldman |
| 11/7/2023 | $66.00 | Buy | B. Riley Securities |
| 8/15/2023 | $58.00 | Outperform | SVB Securities |
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking Science Presentations Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSe
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present a company update. Stockholders of record at the close of business on March 24, 2025 are entitled to vote at Cytokinetics' Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote m
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26, 2025. The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS). Following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten i
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company is scheduled to participate in the following investor conferences in May: The Citizens Life Sciences Conference: Members of the management team will participate in a fireside chat on Wednesday, May 7, 2025 at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel in New York, NY.2025 RBC Capital Markets Global Healthcare Conference: Members of the management team will participate in a fireside chat on Wednesday, May 21, 2025 at 8:30 AM Eastern Time at the InterContinental New York Barclay Hotel in New York, NY. Interested parties may access the liv
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2025 Earnings Confe
SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on April 15, 2025 it granted stock options to purchase an aggregate of 60,670 shares of common stock and 40,888 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 13 employees, whose employment commenced in March and April, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty biopharmaceutical company building on it
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypert
SOUTH SAN FRANCISCO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on March 14, 2025 it granted stock options to purchase an aggregate of 58,631 shares of common stock, 38,068 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,381 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 13 employees, whose employment commenced in February and March, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of th
SCHEDULE 13G - CYTOKINETICS INC (0001061983) (Subject)
10-Q - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
DEF 14A - CYTOKINETICS INC (0001061983) (Filer)
PRE 14A - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
S-3ASR - CYTOKINETICS INC (0001061983) (Filer)
10-K - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
NEW YORK, March 1, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose employment commenced in November 2020 as a material inducement to their employment. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics’ Board of Directors under the company’s Amended and Restated 2004 Equity Incentive Plan. The stock options that were granted are subject to an exercise price of $16.80 per share, which is equal to the closing price of the Company’s common stock on November 30,
Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00
Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $86.00
Stifel initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $80.00
RBC Capital Mkts initiated coverage of Cytokinetics with a rating of Outperform and set a new price target of $80.00
Goldman downgraded Cytokinetics from Buy to Neutral and set a new price target of $60.00 from $85.00 previously
UBS downgraded Cytokinetics from Buy to Neutral and set a new price target of $92.00 from $61.00 previously
Morgan Stanley downgraded Cytokinetics from Overweight to Equal-Weight and set a new price target of $90.00 from $60.00 previously
Goldman initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $50.00
B. Riley Securities initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $66.00
SVB Securities initiated coverage of Cytokinetics with a rating of Outperform and set a new price target of $58.00
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2025 Earnings Confe
Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2024 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2024. The company also provided full year 2025 financial guidance. "The fourth quarter of 2024 capped off
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: C
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Plan to Advance CK-089, Fast Skeletal Muscle Troponin Activator, into First-In-Human Study in Q4 2024 ~$1.3 Billion in Cash, Cash Equivalents and Investments as of September 30, 2024 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the third quarter of 2024. "The progress we made in the third quarter reflects disciplined planning and prudent
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report third quarter results on November 6, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cyt
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients with Obstructive HCM Treated with Aficamten Company to Host Conference Call and Webcast Tuesday, September 3rd at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data related to the safety and long-term use of aficamten were presented in a Late Breaking Clinical Trial presentation and oral presentation at the European Society of Cardiology Congress
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers with Aficamten Presentations Accompanied by Four Simultaneous Journal Publications Company to Host Conference Call and Webcast Tuesday, September 3rd at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pi
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cyto
Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the primary results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clin
SC 13G - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)